Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an announcement.
Shanghai Haohai Biological Technology Co., Ltd. has released its unaudited third quarterly report for 2025, detailing financial results for the three and nine months ending September 30, 2025. The report, prepared in accordance with Chinese Accounting Standards, highlights the company’s financial performance and is intended to inform shareholders and potential investors about the company’s current financial status. The board emphasizes the importance of understanding the investment risks associated with the company’s financial data.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biotechnology sector. The company, along with its subsidiaries, provides various biological products and services, primarily operating in the Chinese market.
Average Trading Volume: 428,790
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.6B
Find detailed analytics on 6826 stock on TipRanks’ Stock Analysis page.